Novo Nordisk Reports P-IIIa Trial (OASIS 1) Results of Semaglutide for the Treatment of Obesity or Overweight
Shots:
- The 68wk. P-IIIa trial (OASIS 1) evaluating semaglutide (50mg) vs PBO in 667 adults aged ≥18yrs. with obesity or overweight with one or more comorbidities
- The trial met its 1EPs & showed a significant and superior weight loss of 17.4% vs 1.8% after 68wks., 89.2% vs 24.5% reached a weight loss of ≥5% after 68wks. if all people adhered to treatment from a mean baseline body weight of 105.4kg
- Superior weight loss of 15.1% vs 2.4% while 84.9% vs 25.8% achieved a weight loss of ≥5% using the treatment policy estimand (treatment effect regardless of treatment adherence), was safe and well-tolerated profile. The company plans to file for regulatory approval in the US and the EU in 2023
Ref: Globe Newswire | Image: Novo Nordisk
Related news:- Novo Nordisk's Wegovy (semaglutide) Receives CHMP's Recommendation for Approval to Treat Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
